Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/ mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial
Diabetes Obesity and Metabolism2022Vol. 24(8), pp. 1522–1533
Citations Over TimeTop 10% of 2022 papers
Wenying Yang, Xiaolin Dong, Qingju Li, Zhifeng Cheng, Guoyue Yuan, Ming Liu, Jianzhong Xiao, Shenghong Gu, Elisabeth Niemoeller, Lijuan Chen, Ping Lin, Elisabeth Souhami, LixiLan‐O‐AP trial investigators
Abstract
iGlarLixi achieved significant HbA1c reductions, to near-normoglycaemic levels, compared with iGlar or Lixi, with no meaningful additional risk of hypoglycaemia and mitigated body weight gain versus iGlar, with fewer gastrointestinal adverse events versus Lixi. iGlarLixi with specifically adapted ratios may provide an efficacious and well-tolerated treatment option for Asian Pacific people with T2D.
Related Papers
- → Importance of Postprandial Glucose Levels as a Target for Glycemic Control in Type 2 Diabetes(2009)39 cited
- → Exercise and Postprandial Glycemic Control in Type 2 Diabetes(2016)24 cited
- → The rationale for paired pre- and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular risk(2007)18 cited
- → The Role of Self-Monitoring of Blood Glucose During the Treatment of type 2 Diabetes With Medications Targeting Postprandial Hyperglycemia(2007)2 cited
- The Postprandial Glycemic Excursions in Gestational Diabetes Mellitus Patients Revealed by Continuous Glucose Monitoring System(2006)